Skip to content

A Randomized Parallel-Controlled Clinical Study on the Impact of Modified Baduanjin Intervention on Quality of Life and Exercise Tolerance in Patients with Symptomatic Atrial Fibrillation.

A Randomized Parallel-Controlled Clinical Study on the Impact of Modified Baduanjin Intervention on Quality of Life and Exercise Tolerance in Patients with Symptomatic Atrial Fibrillation.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000280
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-02-22
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Treatment group:Conventional antiarrhythmic drugs + modified Baduanjin exercises
Control Group:Conventional antiarrhythmic medications plus brisk walking.

Sponsors

Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) 18 years = age = 85 years; (2) Paroxysmal atrial fibrillation with episode frequency = 2 times/month or persistent atrial fibrillation (with at least one ECG diagnosis); (3) Presence of palpitations symptoms; (4) Stable vital signs and able to complete cardiopulmonary exercise testing; (5) No history of regular training in traditional exercises such as Eight Pieces of Brocade, Tai Chi, or Five Animal Exercises in the past 6 months (defined as weekly training < 1 time or single training session < 15 minutes); (6) Correct understanding of the significance of this study, good compliance with the observer's and evaluator's instructions, voluntary acceptance of clinical trial, and willingness to complete the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with severe pulmonary, hepatic, or renal dysfunction, primary diseases of the hematopoietic system, or severe cardiac dysfunction (NYHA Class IV); (2) Patients with mental illness that is poorly controlled; (3) Patients with a heart rate below 50 beats per minute (e.g., thoseto receive a pacemaker); (4) Pregnant or breastfeeding women; (5) Patients in the terminal stage of malignant tumors with cachexia; (6) Patients unable to tolerate cardiopulmonary exercise testing.

Design outcomes

Primary

MeasureTime frame
EHRA Atrial Fibrillation Symptom Evaluation;

Secondary

MeasureTime frame
Cardiopulmonary Exercise Testing (CPET);Dynamic Electrocardiogram (ECG) Assessment;The cumulative number of episodes and duration of palpitations.;Hamilton Anxiety and Depression Scale Assessment;Pittsburgh Sleep Quality Index (PSQI);Echocardiography;ContentBNP;

Countries

People's Republic of China

Contacts

Public ContactWu Qiong

Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital

wuqiong1203@126.com18917047505

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026